SAMSUNG PHARM. Co., LTD. (001360.KS)
KRW 1603.0
(0.25%)
KRW 1603.0
(0.25%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 41.78 Billion KRW | 8.32% |
| 2022 | 38.58 Billion KRW | 40.69% |
| 2021 | 27.42 Billion KRW | 35.43% |
| 2020 | 20.24 Billion KRW | 38.49% |
| 2019 | 14.62 Billion KRW | 9.33% |
| 2018 | 13.37 Billion KRW | 11.8% |
| 2017 | 11.96 Billion KRW | -30.44% |
| 2016 | 17.19 Billion KRW | 30.87% |
| 2015 | 13.14 Billion KRW | -53.59% |
| 2014 | 28.31 Billion KRW | -1.73% |
| 2013 | 28.81 Billion KRW | 54.91% |
| 2012 | 18.6 Billion KRW | 6.36% |
| 2011 | 17.48 Billion KRW | 21.79% |
| 2010 | 14.36 Billion KRW | -0.03% |
| 2009 | 14.36 Billion KRW | 24.1% |
| 2008 | 11.57 Billion KRW | -14.74% |
| 2007 | 13.57 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 7.5 Billion KRW | -18.05% |
| 2024 Q2 | 11.6 Billion KRW | 54.62% |
| 2023 Q3 | -9.06 Billion KRW | 23.79% |
| 2023 Q4 | 9.15 Billion KRW | 201.04% |
| 2023 Q1 | 11.06 Billion KRW | 2.97% |
| 2023 FY | 41.78 Billion KRW | 8.32% |
| 2023 Q2 | -11.89 Billion KRW | -207.45% |
| 2022 FY | 38.58 Billion KRW | 40.69% |
| 2022 Q1 | 8.42 Billion KRW | 4.2% |
| 2022 Q2 | 9.15 Billion KRW | 8.66% |
| 2022 Q3 | 10.24 Billion KRW | 11.85% |
| 2022 Q4 | 10.74 Billion KRW | 4.93% |
| 2021 Q3 | 5.84 Billion KRW | -10.14% |
| 2021 Q1 | 7 Billion KRW | 24.52% |
| 2021 FY | 27.42 Billion KRW | 35.43% |
| 2021 Q2 | 6.49 Billion KRW | -7.17% |
| 2021 Q4 | 8.08 Billion KRW | 38.5% |
| 2020 Q2 | 6.11 Billion KRW | 42.9% |
| 2020 Q4 | 5.62 Billion KRW | 26.45% |
| 2020 FY | 20.24 Billion KRW | 38.49% |
| 2020 Q1 | 4.27 Billion KRW | 0.0% |
| 2020 Q3 | 4.44 Billion KRW | -27.3% |
| 2019 Q2 | 3.84 Billion KRW | 1.37% |
| 2019 Q1 | 3.79 Billion KRW | 18.95% |
| 2019 FY | 14.62 Billion KRW | 9.33% |
| 2019 Q3 | 8.25 Billion KRW | 114.82% |
| 2018 Q4 | 3.18 Billion KRW | -7.1% |
| 2018 Q2 | 3.71 Billion KRW | 22.04% |
| 2018 FY | 13.37 Billion KRW | 11.8% |
| 2018 Q1 | 3.04 Billion KRW | 8.27% |
| 2018 Q3 | 3.43 Billion KRW | -7.56% |
| 2017 Q3 | 2.8 Billion KRW | -0.87% |
| 2017 Q2 | 2.82 Billion KRW | -19.76% |
| 2017 Q1 | 3.52 Billion KRW | -4.8% |
| 2017 FY | 11.96 Billion KRW | -30.44% |
| 2017 Q4 | 2.8 Billion KRW | 0.24% |
| 2016 Q4 | 3.7 Billion KRW | -23.87% |
| 2016 FY | 17.19 Billion KRW | 30.87% |
| 2016 Q3 | 4.86 Billion KRW | -0.2% |
| 2016 Q2 | 4.87 Billion KRW | 29.4% |
| 2016 Q1 | 3.76 Billion KRW | -8.49% |
| 2015 Q1 | 2.31 Billion KRW | -88.9% |
| 2015 Q2 | 2.78 Billion KRW | 20.64% |
| 2015 Q3 | 3.36 Billion KRW | 20.62% |
| 2015 Q4 | 4.11 Billion KRW | 22.25% |
| 2015 FY | 13.14 Billion KRW | -53.59% |
| 2014 Q4 | 20.83 Billion KRW | 1169.87% |
| 2014 Q3 | 1.64 Billion KRW | -46.67% |
| 2014 Q2 | 3.07 Billion KRW | 11.1% |
| 2014 Q1 | 2.76 Billion KRW | -82.48% |
| 2014 FY | 28.31 Billion KRW | -1.73% |
| 2013 Q2 | 4.47 Billion KRW | 3.41% |
| 2013 Q3 | 4.2 Billion KRW | -5.89% |
| 2013 Q4 | 15.8 Billion KRW | 275.49% |
| 2013 Q1 | 4.32 Billion KRW | -35.19% |
| 2013 FY | 28.81 Billion KRW | 54.91% |
| 2012 Q2 | 4.28 Billion KRW | 17.89% |
| 2012 Q1 | 3.63 Billion KRW | -18.56% |
| 2012 Q3 | 3.99 Billion KRW | -6.77% |
| 2012 Q4 | 6.67 Billion KRW | 66.94% |
| 2012 FY | 18.6 Billion KRW | 6.36% |
| 2011 FY | 17.48 Billion KRW | 21.79% |
| 2011 Q3 | 4.38 Billion KRW | -6.84% |
| 2011 Q4 | 4.46 Billion KRW | 1.8% |
| 2011 Q1 | 3.92 Billion KRW | 4.58% |
| 2011 Q2 | 4.7 Billion KRW | 19.99% |
| 2010 Q3 | 3.37 Billion KRW | -13.63% |
| 2010 FY | 14.36 Billion KRW | -0.03% |
| 2010 Q2 | 3.9 Billion KRW | 17.61% |
| 2010 Q1 | 3.32 Billion KRW | -20.36% |
| 2010 Q4 | 3.75 Billion KRW | 11.19% |
| 2009 Q2 | 2.61 Billion KRW | -27.19% |
| 2009 Q3 | 3.97 Billion KRW | 51.78% |
| 2009 Q1 | 3.59 Billion KRW | 29.35% |
| 2009 FY | 14.36 Billion KRW | 24.1% |
| 2009 Q4 | 4.17 Billion KRW | 4.96% |
| 2008 Q1 | 3.12 Billion KRW | -19.43% |
| 2008 Q2 | 2.58 Billion KRW | -17.05% |
| 2008 FY | 11.57 Billion KRW | -14.74% |
| 2008 Q3 | 3.08 Billion KRW | 19.01% |
| 2008 Q4 | 2.78 Billion KRW | -9.77% |
| 2007 Q3 | 4.35 Billion KRW | 62.88% |
| 2007 Q2 | 2.67 Billion KRW | 0.11% |
| 2007 Q4 | 3.87 Billion KRW | -11.04% |
| 2007 FY | 13.57 Billion KRW | 0.0% |
| 2007 Q1 | 2.67 Billion KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 47.25 Billion KRW | 11.564% |
| Dong-A Socio Holdings Co., Ltd. | 297.99 Billion KRW | 85.976% |
| Ildong Holdings Co., Ltd. | 278.43 Billion KRW | 84.992% |
| HANDOK Inc. | 153.76 Billion KRW | 72.823% |
| Kukje Pharma Co., Ltd. | 69.21 Billion KRW | 39.622% |
| Yuhan Corporation | 489.94 Billion KRW | 91.471% |
| Dong-A ST Co., Ltd. | 306.95 Billion KRW | 86.386% |
| Hanmi Pharm. Co., Ltd. | 610.97 Billion KRW | 93.16% |
| Hanall Biopharma Co.,Ltd | 71.98 Billion KRW | 41.946% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | 76.004% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.05 Billion KRW | -4.335% |
| MYUNGMOON Pharm co.,Ltd | 93.55 Billion KRW | 55.33% |
| Hana Pharm Co., Ltd. | 114.72 Billion KRW | 63.574% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | 11.564% |
| Ilsung Pharmaceuticals Co., Ltd. | 42.47 Billion KRW | 1.606% |
| REYON Pharmaceutical Co., Ltd. | 75.04 Billion KRW | 44.317% |
| Aprogen pharmaceuticals,Inc. | 58.64 Billion KRW | 28.741% |
| JW Holdings Corporation | 301.25 Billion KRW | 86.128% |
| Ildong Pharmaceutical Co., Ltd. | 260.95 Billion KRW | 83.986% |
| Chong Kun Dang Pharmaceutical Corp. | 408.65 Billion KRW | 89.774% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 82.508% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | 67.267% |
| Hyundai Pharmaceutical Co., Ltd. | 68.31 Billion KRW | 38.825% |
| Samil Pharmaceutical Co.,Ltd | 65.75 Billion KRW | 36.443% |
| Jeil Pharmaceutical Co.,Ltd | 174.92 Billion KRW | 76.11% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | 11.564% |
| Kwang Dong Pharmaceutical Co., Ltd. | 249.12 Billion KRW | 83.225% |
| Daewoong pharmaceutical Co.,Ltd | 560.43 Billion KRW | 92.543% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 82.508% |
| Yuhan Corporation | 489.94 Billion KRW | 91.471% |
| Jeil Pharma Holdings Inc | 193.66 Billion KRW | 78.422% |
| Yungjin Pharm. Co., Ltd. | 69.46 Billion KRW | 39.844% |
| Suheung Co., Ltd. | 56.03 Billion KRW | 25.419% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 82.508% |
| Samjin Pharmaceuticals Co., Ltd. | 126.39 Billion KRW | 66.937% |
| Korea United Pharm Inc. | 118.21 Billion KRW | 64.649% |
| CKD Bio Corp. | 25.19 Billion KRW | -65.859% |
| Daewon Pharmaceutical Co., Ltd. | 221.99 Billion KRW | 81.176% |
| Dongwha Pharm.Co.,Ltd | 165.11 Billion KRW | 74.69% |
| Whan In Pharm Co.,Ltd. | 66.41 Billion KRW | 37.08% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | 67.267% |
| Chong Kun Dang Holdings Corp. | 350.71 Billion KRW | 88.085% |
| Boryung Corporation | 285.16 Billion KRW | 85.345% |
| Bukwang Pharmaceutical Co., Ltd. | 87.54 Billion KRW | 52.264% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | 76.004% |
| JW Lifescience Corporation | 20.26 Billion KRW | -106.25% |